Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Charlotte-Paige Rolle

11PUBLICATIONS
10CO-AUTHORS
Separation technologiesPharmacogenomicsGene and molecular therapyAboriginal and Torres Strait Islander theory of change models for healthImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

Sort by Publication Date:
|Jun 12, 2026
Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.

|Sep 02, 2025
VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.

Peter A Leone, Alejandro Ferro, Charlotte-Paige Rolle

|Mar 26, 2025
Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials.

Charlotte-Paige Rolle, José R Arribas, Roberto Ortiz

|Mar 11, 2025
Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeks.

Charlotte-Paige Rolle, Jeffrey Garrett, Jamie Castano

|Oct 17, 2024
Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study.

Charlotte-Paige Rolle, Jamie Castano, Vu Nguyen

|Mar 27, 2023
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.

Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh

Pageof 2

Frequent Collaborators

1 joint publications

Federico Hinestrosa

1 joint publications

Marina Klein

1 joint publications

Pedro Cahn

1 joint publications

Margaret Gartland

1 joint publications

Sebastian A Nuñez

1 joint publications

Pere Domingo

1 joint publications

Roberto Güerri-Fernandez

1 joint publications

Vicente Estrada

1 joint publications

Gabriela L Ghita

1 joint publications

Jose R Castillo-Mancilla

Frequent Collaborators

1 joint publications

Federico Hinestrosa

1 joint publications

Marina Klein

1 joint publications

Pedro Cahn

1 joint publications

Margaret Gartland